Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inaxaplin PK in severe renal impairment
NCT05865171Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inaxaplin in APOL1-mediated kidney disease (AMKD) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at Day 7 and Area Under the Concentration Versus Time Curve Extrapolated to Infinity at Day 7. Started Jun 2023; status: completed.
02
Drugs
inaxaplin
03
Conditions
APOL1-mediated kidney disease (AMKD)
Beyond the preview
Go deeper on NCT05865171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05865171.